POAI 8-k
On June 25, 2020, Predictive Oncology Inc. (the “Company”) entered into Warrant Exercise Letter Agreements (the “Exercise Agreements”) with certain accredited institutional investors (the “Holders”) holding warrants of the Company (the “Existing Warrants”) to purchase up to an aggregate of 1,396,826 shares of Common Stock, issued on May 8, 2020, exercisable immediately at $1.45 per share of Common Stock and terminating five and one-half years after the date of issuance. The resale of the shares of Common Stock underlying the Existing Warrants (the “Warrant Shares”) has been registered pursuant to the registration statement on Form S-1 (File No. 333-239207) (the “Registration Statement”) previously filed with, and declare effective